Skip to main content

Advertisement

SpringerLink
Log in

Differing coagulation profiles of patients with monoclonal gammopathy of undetermined significance and multiple myeloma

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

An Erratum to this article was published on 15 November 2014

Abstract

The link between myeloma and thrombosis is well established. Monoclonal gammopathy of undetermined significance (MGUS) has also been associated with an increased risk of thrombosis. It was recently demonstrated that patients with myeloma display changes in thromboelastometry that may indicate a prothrombotic state. There is little data with regard to changes in thromboelastography in patients with myeloma or MGUS. The aim of this study was to investigate the differing coagulation profiles of patients of patients with myeloma and MGUS by means of conventional coagulation tests and thromboelastography. Blood was taken by direct venepuncture from patients with myeloma, MGUS and normal controls. Routine coagulation tests were performed in an accredited hospital laboratory. Thromboelastography (TEG®) was performed as per the manufacturer’s protocol. Eight patients were recruited in each group. Patients with myeloma had a significantly lower mean haemoglobin level than patients with MGUS or normal controls (p < 0.001). Pateints with myeloma had a significantly more prolonged mean prothrombin time than normal controls (p = 0.018) but not patients with MGUS. Patients with myeloma had significantly higher median D-dimer levels than normal controls (p = 0.025), as did patients with MGUS (p = 0.017). Patients with myeloma had a significantly higher mean factor VIII level than normal controls (p = 0.009) and there was a non-significant trend towards patients with MGUS having higher factor VIII levels than normal controls (p = 0.059). There was no significant difference in thromboelastographic parameters between the three groups. Patients with MGUS appear to have a distinct coagulation profile which is intermediate between patients with myeloma and normal controls.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Trousseau A (1865) Clinique Medicale de l’Hotel-Dieu de Paris. 2nd ed

  2. Yu JL, May L, Lhotak V, Shahrzad S, Shirasawa S, Weitz JI et al (2005) Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 105(4):1734–1741 Epub 2004/10/21

    Article  CAS  PubMed  Google Scholar 

  3. Khorana AA, Francis CW, Culakova E, Fisher RI, Kuderer NM, Lyman GH (2006) Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 24(3):484–490 Epub 2006/01/20

    Article  PubMed  Google Scholar 

  4. Catovsky D, Ikoku NB, Pitney WR, Galton DA (1970) Thromboembolic complications in myelomatosis. Br Med J 3(5720):438–439 Epub 1970/08/22

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Lopez-Pedrera C, Barbarroja N, Dorado G, Siendones E, Velasco F (2006) Tissue factor as an effector of angiogenesis and tumor progression in hematological malignancies. Leukemia 20(8):1331–1340 Epub 2006/05/27

    Article  CAS  PubMed  Google Scholar 

  6. Elice F, Fink L, Tricot G, Barlogie B, Zangari M (2006) Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol 134(4):399–405 Epub 2006/08/03

    Article  CAS  PubMed  Google Scholar 

  7. Rickles FR, Shoji M, Abe K (2001) The role of the hemostatic system in tumor growth, metastasis, and angiogenesis: tissue factor is a bifunctional molecule capable of inducing both fibrin deposition and angiogenesis in cancer. Int J Hematol 73(2):145–150 Epub 2001/05/25

    Article  CAS  PubMed  Google Scholar 

  8. Zangari M, Saghafifar F, Mehta P, Barlogie B, Fink L, Tricot G (2003) The blood coagulation mechanism in multiple myeloma. Semin Thromb Hemost 29(3):275–282 Epub 2003/07/31

    Article  CAS  PubMed  Google Scholar 

  9. Rajkumar SV, Leong T, Roche PC, Fonseca R, Dispenzieri A, Lacy MQ et al (2000) Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 6(8):3111–3116 Epub 2000/08/24

    CAS  PubMed  Google Scholar 

  10. Larocca A, Cavallo F, Bringhen S, Di Raimondo F, Falanga A, Evangelista A et al (2012) Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood 119(4):933–939 quiz 1093. Epub 2011/08/13

    Article  CAS  PubMed  Google Scholar 

  11. Palumbo A, Facon T, Sonneveld P, Blade J, Offidani M, Gay F et al (2008) Thalidomide for treatment of multiple myeloma: 10 years later. Blood 111(8):3968–3977 Epub 2008/02/05

    Article  CAS  PubMed  Google Scholar 

  12. Kristinsson SY, Fears TR, Gridley G, Turesson I, Mellqvist UH, Bjorkholm M et al (2008) Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 112(9):3582–3586 Epub 2008/06/19

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Gregersen H, Norgaard M, Severinsen MT, Engebjerg MC, Jensen P, Sorensen HT (2011) Monoclonal gammopathy of undetermined significance and risk of venous thromboembolism. Eur J Haematol 86(2):129–134 Epub 2010/10/15

    Article  PubMed  Google Scholar 

  14. Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, Miguel JS, Barlogie B et al (2008) Prevention of thalidomide—and lenalidomide-associated thrombosis in myeloma. Leukemia 22(2):414–423

    Article  CAS  PubMed  Google Scholar 

  15. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111(10):4902–4907 Epub 2008/01/25

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R et al (2010) Prediction of venous thromboembolism in cancer patients. Blood 116(24):5377–5382 Epub 2010/09/11

    Article  CAS  PubMed  Google Scholar 

  17. Crowley MP, Eustace JA, O’Shea SI, Gilligan OM (2014) Venous thromboembolism in patients with myeloma: incidence and risk factors in a “Real-World” population. Clin Appl Thromb Hemost 20:600–606 Epub 2014/02/04

    Article  PubMed  Google Scholar 

  18. Trelinski J, Misiewicz M, Robak M, Smolewski P, Chojnowski K (2014) Assessment of rotation thromboelastometry (ROTEM) parameters in patients with multiple myeloma at diagnosis. Thromb Res 133:667–670 Epub 2014/01/24

    Article  CAS  PubMed  Google Scholar 

  19. Bowbrick VA, Mikhailidis DP, Stansby G (2000) The use of citrated whole blood in thromboelastography. Anesth Analg 90(5):1086–1088 Epub 2000/04/27

    Article  CAS  PubMed  Google Scholar 

  20. Pandey S, Post SR, Alapat DV, Smock KJ, Post GR (2013) Prolonged prothrombin time correlates with serum monoclonal protein concentration in patients with plasma cell dyscrasia. Int J Lab Hematol 35(4):421–427 Epub 2012/12/12

    Article  CAS  PubMed  Google Scholar 

  21. Kato A, Takano H, Ichikawa A, Koshino M, Igarashi A, Hattori K et al (2013) A retrospective cohort study of venous thromboembolism(VTE) in 1035 Japanese myeloma patients treated with thalidomide; lower incidence without statistically significant association between specific risk factors and development of VTE and effects of thromboprophylaxis with aspirin and warfarin. Thromb Res 131(2):140–144 Epub 2012/12/13

    Article  CAS  PubMed  Google Scholar 

  22. Kopitsky RG, Switzer ME, Williams RS, McKee PA (1983) The basis for the increase in factor VIII procoagulant activity during exercise. Thromb Haemost 49(1):53–57 Epub 1983/02/28

    CAS  PubMed  Google Scholar 

  23. Cash JD, Gader AM, da Costa J (1974) Proceedings: the release of plasminogen activator and factor VIII to lysine vasopressin, arginine vasopressin, I-desamino-8-d-arginine vasopressin, angiotensin and oxytocin in man. Br J Haematol 27(2):363–364 Epub 1974/06/01

    CAS  PubMed  Google Scholar 

  24. Strauss HS, Diamond LK (1963) Elevation of factor Viii (antihemophilic factor) during pregnancy in normal persons and in a patient with von Willebrand’s disease. N Engl J Med 269:1251–1252 Epub 1963/12/05

    Article  CAS  PubMed  Google Scholar 

  25. Holmberg L, Nilsson IM (1974) AHF related protein in clinical praxis. Scand J Haematol 12(3):221–231 Epub 1974/01/01

    Article  CAS  PubMed  Google Scholar 

  26. Bloom AL (1979) The biosynthesis of factor VIII. Clin Haematol 8(1):53–77 Epub 1979/02/01

    CAS  PubMed  Google Scholar 

  27. Gomperts ED, Shulman G, Lynch SR (1976) Factor VIII and factor-VIII-related antigen in multiple myelomatosis and related conditions. Br J Haematol 32(2):249–255 Epub 1976/02/01

    Article  CAS  PubMed  Google Scholar 

  28. Minnema MC, Fijnheer R, De Groot PG, Lokhorst HM (2003) Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haemost 1(3):445–449 Epub 2003/07/23

    Article  CAS  PubMed  Google Scholar 

  29. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR (1995) Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 345(8943):152–155 Epub 1995/01/21

    Article  CAS  PubMed  Google Scholar 

  30. O’Donnell J, Tuddenham EG, Manning R, Kemball-Cook G, Johnson D, Laffan M (1997) High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to the acute phase reaction. Thromb Haemost 77(5):825–828 Epub 1997/05/01

    PubMed  Google Scholar 

  31. Kristinsson SY (2010) Thrombosis in multiple myeloma. Hematology Am Soc Hematol Educ Program 2010:437–444 Epub 2011/01/18

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

MP Crowley has received research funding from Leo Pharma.

Author information

Authors and Affiliations

  1. Department of Haematology, Cork University Hospital, Wilton, Cork, Ireland

    Maeve P. Crowely, Shane Quinn, Eoin Coleman, Oonagh M. Gilligan & Susan I. O. Shea

  2. HRB Clinical Research Facility, University College, Cork, Ireland

    Joseph A. Eustace

Authors
  1. Maeve P. Crowely
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shane Quinn
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eoin Coleman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Joseph A. Eustace
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Oonagh M. Gilligan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Susan I. O. Shea
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maeve P. Crowely.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Crowely, M.P., Quinn, S., Coleman, E. et al. Differing coagulation profiles of patients with monoclonal gammopathy of undetermined significance and multiple myeloma. J Thromb Thrombolysis 39, 245–249 (2015). https://doi.org/10.1007/s11239-014-1140-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-014-1140-z

Keywords

Search

Navigation